Potassium Carbonate → 3-[2'-(2,3-dihydroindole-1-carbonyl)-3,4,5,6-tetrahydro-2H-1,4'-bipyridinyl-4-yl]-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one
반응식
Cl[C:2]1[CH:7]=[CH:6][N:5]=[C:4]([C:8]([N:10]2[C:18]3[C:13](=[CH:14][CH:15]=[CH:16][CH:17]=3)[CH2:12][CH2:11]2)=[O:9])[CH:3]=1.C(=O)([O-])[O-].[K+].[K+].[NH:25]1[CH2:30][CH2:29][CH:28]([N:31]2[CH2:37][CH2:36][C:35]3[CH:38]=[CH:39][CH:40]=[CH:41][C:34]=3[NH:33][C:32]2=[O:42])[CH2:27][CH2:26]1>C1COCC1>[N:10]1([C:8]([C:4]2[CH:3]=[C:2]([N:25]3[CH2:26][CH2:27][CH:28]([N:31]4[CH2:37][CH2:36][C:35]5[CH:38]=[CH:39][CH:40]=[CH:41][C:34]=5[NH:33][C:32]4=[O:42])[CH2:29][CH2:30]3)[CH:7]=[CH:6][N:5]=2)=[O:9])[C:18]2[C:13](=[CH:14][CH:15]=[CH:16][CH:17]=2)[CH2:12][CH2:11]1참가 물질
5
반응물 3
생성물 1
시약·촉매·용매 1
실험 절차
110 mg (0.43 mmol) (4-chloro-pyridin-2-yl)-(2,3-dihydro-indol-1-yl)-methanone, 150 mg (1.0 mmol) potassium carbonate and 100 mg (0.41 mmol) 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one in 10 mL THF were refluxed for 3 days. Then the reaction mixture was evaporated down using the rotary evaporator, taken up in 20 mL xylene and refluxed for a further 3 days. The solid was filtered off and the filtrate evaporated down i. vac. The residue was dissolved in DMF and purified by preparative HPLC. The product fractions were combined and lyophilised.
후처리
- customThen the reaction mixture was evaporated down
- customthe rotary evaporator
- temperaturerefluxed for a further 3 days
- filtrationThe solid was filtered off
- customthe filtrate evaporated down i
- dissolutionThe residue was dissolved in DMF
- custompurified by preparative HPLC
출처 및 근거
- ORD 기록
- ord-a713b8b762d3463ca804602f6597b9ec
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- US08829006B2
반응 노트
불러오는 중…